摘要
目的:探讨醒脑静注射液对甲型H1N1流感中急性时相蛋白(APPs)含量变化的影响及其疗效观察。方法:根据诊断标准和APACHEII评分将46例确诊为重症甲型H1N1流感患者分两组:治疗组24例在常规治疗基础上加醒脑静注射液;对照组22例仅常规治疗。以第1、5、7、14天4个时间点为观察点,动态测定46例甲流患者血清APPs含量。轻症组在门诊随机选取23例进行分析。结果:重症患者CRP、α1-AT、α1-AG和HP水平较轻症组有显著差异(P<0.01)。重症患者CRP、α1-AT在第5~7天后均达高峰,α1-AT高峰期稍滞后,病情缓解后可下降。治疗组第5、7天CRP,α1-AT值下降幅度与对照组比较有统计学差异(P<0.05);而治疗组与对照组α1-AG和HP水平均无统计学差异。结论:醒脑静注射液在治疗重症甲型H1N1流感中可以通过对急性时相蛋白CRP和α1-AT的抑制作用,从而使炎症期高峰下移,改善疾病的预后。
Objective:To explore the impact of Xingnaojing Injection on acute phase proteins(APPs) and its clinical efficacy in patients of H1N1 influenza A.Methods:46 diagnosed patients of severe symptoms were randomly divided into Control Group(22 cases) and Treatment Group(24 cases).The Control Group was administered conventional western medicine and comprehensive treatment. While the Treatment Group were supplemented Xingnaojing Injection expect for the regular treatment. 46 cases of serum levels of APPs,including C-reactive protein (CRP),α1anti-trypsin protease (α1-AT),α1-acid glycoprotein (α1-AG) and haptoglobin (HP),were dynamically determined at points of 1,5,7,14 days after H1N1 influenza A were diagnosed. 23 cases were randomly selected as Mild group of patients in the out patient department.Results:The level of CRP,α1-AT,α1-AG,and HP in Critically-ill Patients Group were significantly different compared to Severe Patients Group (P0.01);the indexes mentioned above were also significantlydifferent between the Severe Group of patients and Mild Group patients(P0.01). CRP,α1-AT increased to a peak value in 5~7d in Critically-ill Group patients and Severe group of patients. But α1-AT peak slightly lagged behind.CRP value of Critical illness patients was higher than Severe patient at the 1,7,14d(P0.01 or P0.05).α1-AG,and HP levels of Seriously ill patients was lower than those in severe group at the 1,14 days (P0.05).Conclusion:Xingnaojing Injection could reduce serum CRP and α1-AT level effectively and improves the recovery of the diseases.
出处
《中华中医药学刊》
CAS
2010年第9期2015-2016,共2页
Chinese Archives of Traditional Chinese Medicine